	US 12,435,124 B2
	Compositions and methods for treating CEACAM positive cancers
Xueyin Wang, Agoura Hills, CA (US); Carl Alexander Kamb, Agoura Hills, CA (US); Han Xu, Agoura Hills, CA (US); Mark L. Sandberg, Agoura Hills, CA (US); and Dora Toledo Warshaviak, Agoura Hills, CA (US)
Assigned to A2 Biotherapeutics, Inc., Agoura Hills, CA (US)
Filed by A2 Biotherapeutics, Inc., Agoura Hills, CA (US)
Filed on Jul. 22, 2022, as Appl. No. 17/814,434.
Application 17/814,434 is a division of application No. 17/517,559, filed on Nov. 2, 2021, granted, now 11,433,100.
Application 17/517,559 is a continuation of application No. PCT/US2021/046774, filed on Aug. 19, 2021.
Claims priority of provisional application 63/068,244, filed on Aug. 20, 2020.
Prior Publication US 2023/0172983 A1, Jun. 8, 2023
Int. Cl. C07K 14/705 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01)

CPC C07K 14/70578 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/4266 (2025.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); A61K 2239/50 (2023.05)]

19 Claims

1. A polynucleotide comprising one or more polynucleotide sequences encoding:

a. a first receptor polypeptide, comprising an extracellular ligand binding domain specific to CEA cell adhesion molecule 5 (CEA); and

b. a second receptor polypeptide, comprising an extracellular ligand binding domain specific to HLA-A*02,

wherein the first receptor is an activator receptor responsive to CEA; and wherein the second receptor is an inhibitory receptor responsive to HLA-A*02;

wherein the extracellular ligand binding domain of the first receptor comprises a variable heavy (VH) portion comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NOS: 55, 56, and 57, respectively, and a variable light (VL) portion comprising CDRs CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NOS: 59, 61, and 63, respectively;

and

wherein the extracellular ligand binding domain of the second receptor comprises a VH portion comprising CDRs CDR-H1, CDR-H2, and CDR-H3 of SEQ ID NOS: 106, 107, and 108, respectively, and a VL portion comprising CDRs CDR-L1, CDR-L2, and CDR-L3 of SEQ ID NOS: 103, 104, and 105, respectively.